Documenting Device Changes in Biological Risk Assessments: Part Two
This whitepaper, the second in a four-part series covering different examples of device changes to be documented...
This whitepaper, the second in a four-part series covering different examples of device changes to be documented...
The production of biological products in biopharmaceutical manufacturing involves significant risks of viral contamination from human and...
Contamination from ethylene glycol and diethylene glycol in liquid formulation poses a high risk to patient safety....
This whitepaper focuses on the importance of disinfectant validations based on real-world conditions to maintain cGMP compliance...
“Device changes can range in complexity, making it critical that each change be treated uniquely and assessed...
As reusable medical devices have advanced, the importance of effective decontamination methods (cleaning, disinfection, and/or sterilization) has...
The 2024 updates to the ISO 18562 series of standards bring quite a few changes. In this...
In this webinar, presented by our Senior Expert LC/MS, Ruud Cuyvers, you’ll expand your knowledge on unexpected impurities in Drug...
VH2O2 sterilization may leave hydrogen peroxide residuals on the device materials after the sterilization process whose toxicological...
Biocompatibility assessments involve extensive evaluation, and changing the sterilization modality, such as to VH2O2, can trigger considerable,...